neuroCleus is raising 10 million euros from investors for clinical trials with its technology. This technology should improve Parkinson's diagnosis.
Neurodegenerative diseases are increasingly common and affect an estimated one in three people worldwide, yet these conditions are difficult to diagnose. The number of people with Parkinson's disease is expected to double to 13 million by 2040. Yet one in five patients is still misdiagnosed.
Irreversible brain damage
When the disease is finally diagnosed correctly, irreversible brain damage has often already occurred. This can lead to the loss of 65% of affected neurons. The main reason for this, according to neuroCleus, is that doctors mainly rely on clinical observations without quantitative results, such as the 'follow my finger' test. However, advanced technologies such as imaging are costly, not widely available and often fail to detect early-stage abnormalities.
neuroCleus is the developer of a wearable medical device that derives neurological biomarkers from eye movements in minutes. The compact device takes infrared images of each eye while the patient performs simple visual tasks. AI algorithms calculate objective and reproducible biomarkers on this basis.
Alternative to 'follow my finger' test
The device is plug-and-play and provides insight within minutes. neuroCleus supports doctors in detecting neurological abnormalities, offering an alternative to the 'follow my finger' test, which the company describes as subjective.
In the future, the company also aims to collect more clinical data to identify specific pathologies. These include distinguishing Parkinson's from atypical parkinsonism, detecting early signs of Alzheimer's and detecting cognitive impairment after concussion.
MDR certification
NeuroCleus' technology achieved MDR certification in early 2025 and may now carry the CE mark. The company reports that the technology has now been implemented in hospitals in seven European countries.
The company is now raising €10 million during a Series A investment round. Among others, Teampact Ventures, White Fund and the EIC Fund (European Innovation Council) are putting money into the lot. In addition, existing investors InvestBW, Leansquare and Wallonie Entreprendre are also reinvesting, and the company is getting support from Brussels-based IBA (Ion Beam Applications) chairman and CEO Olivier Legrain.
